SCHEMBL9972200

SCHEMBL9972200

O=C(COc1cccc2cccnc12)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.72
ALDH1A1 P00352 4/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
NPC1 O15118 2/20 0.71
RAB9A P51151 2/20 0.71
HPGD P15428 2/20 0.71
TP53 P04637 1/20 0.71
L3MBTL1 Q9Y468 2/20 0.61
SCN3A Q9NY46 1/20 0.59
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
LMNA P02545 1/20 0.58
TSHR P16473 1/20 0.58
MAPT P10636 2/20 0.57
RXFP1 Q9HBX9 1/20 0.55
KDM4E B2RXH2 1/20 0.55
THRB P10828 1/20 0.54
RECQL P46063 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
POLB P06746 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9972178 0.89 PKM (0.67) PKMALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL15113438 0.88 PKM (0.76) PKMALDH1A1SMN1; SMN2HPGDTP53
SCHEMBL9972182 0.86 PKM (0.70) PKMALDH1A1SMN1; SMN2L3MBTL1SCN3A
SCHEMBL9972212 0.85 PKM (0.65) PKMALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL9972211 0.84 PKM (0.68) PKMALDH1A1SMN1; SMN2HPGDL3MBTL1
SCHEMBL15113353 0.84 PKM (0.85) PKMALDH1A1SMN1; SMN2L3MBTL1SCN3A
SCHEMBL15116305 0.84 PKM (0.73) PKMSMN1; SMN2SCN3AMEN1KMT2A
SCHEMBL15113337 0.83 PKM (0.79) PKMALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL15116293 0.83 PKM (1.00) PKMALDH1A1SMN1; SMN2SCN3AMEN1
SCHEMBL15113262 0.83 PKM (0.79) PKMALDH1A1SMN1; SMN2SCN3AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309543-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-13 US disclosed
US-8309543-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-13 US disclosed
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 US disclosed
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 US disclosed
US-8202861-B2 Drugs for various disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-19 US disclosed
US-8202861-B2 Drugs for various disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS SCNN1G, KCNN3, KCNN2 PKM 4054/4885ALDH1A1 2811/4885SMN1; SMN2 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.